A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Cytomegalovirus (CMV) Genotype (UL97/UL54)
Test Code13948
CPT Codes
87910, 87900
Includes
Ganciclovir Resistance
Maribavir Resistance
Foscarnet Resistance
Cidofovir Resistance
UL97 Kinase Mutations
UL54 Polymerase Mutations
Maribavir Resistance
Foscarnet Resistance
Cidofovir Resistance
UL97 Kinase Mutations
UL54 Polymerase Mutations
Preferred Specimen
1 mL whole blood collected in an EDTA (lavender-top) tube or
1 mL plasma collected in an EDTA (lavender-top) tube or PPT tube
1 mL plasma collected in an EDTA (lavender-top) tube or PPT tube
Minimum Volume
0.3 mL
Instructions
Whole blood: Collect whole blood in sterile tubes containing EDTA as anticoagulant. Store refrigerated or frozen.
Plasma: Collect blood in sterile tubes containing EDTA as anticoagulant or in PPT tubes. Store collected whole blood at room temperature and separate plasma from cells within 2 hours of collection. Transfer plasma to sterile plastic screw-cap tubes and store refrigerated or frozen. If blood is collected in a plasma preparation tube, centrifuge within 2 hours of collection and store refrigerated or frozen. It is not necessary to transfer the plasma from a plasma preparation tube to aliquot tubes.
Plasma: Collect blood in sterile tubes containing EDTA as anticoagulant or in PPT tubes. Store collected whole blood at room temperature and separate plasma from cells within 2 hours of collection. Transfer plasma to sterile plastic screw-cap tubes and store refrigerated or frozen. If blood is collected in a plasma preparation tube, centrifuge within 2 hours of collection and store refrigerated or frozen. It is not necessary to transfer the plasma from a plasma preparation tube to aliquot tubes.
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 48 hours
Refrigerated: 8 days
Frozen: 30 days
Refrigerated: 8 days
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Samples containing heparin • Unspun PPT tubes
Methodology
Polymerase Chain Reaction (PCR) • Next Generation Sequencing (NGS)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Mon, Wed; Report available: 5-8 days
Reference Range
See Laboratory Report
Clinical Significance
Treatment of CMV diseases includes five licensed drugs: Ganciclovir, Maribavir, Foscarnet, Cidofovir, and Letermovir. These drugs inhibit the viral phosphotransferase, DNA polymerase or terminase through various mechanisms. Over time, as CMV makes copies of itself, viral genes can acquire mutations. These mutations may make CMV resistant to the effects of antiviral drugs. Therefore, it is important to detect resistance as quickly and accurately as possible for proper management of CMV infection.
Performing Laboratory
Quest Diagnostics Nichols Institute (IFD) SJC
33608 Ortega Highway
San Juan Capistrano, CA 92675
Last Updated: March 5, 2025